Skip to navigationSkip to main contentSkip to right columnADVERTISEMENTCory Renauer, The Motley FoolSun, June 7, 2026 at 2:48 PM GMT+2 4 min readAndrew Reardon, CLO & Secretary at Ligand (NASDAQ:LGND), reported the sale of 5,000 shares of Common Stock for approximately ~$1.14 million on June 1, 2026, following the immediate exercise and disposition of stock options under an SEC Form 4 filing: SEC Form 4 filingTransaction summaryMetricValueShares traded (direct)5,000Transaction value~$1.1 millionPost-transaction shares (direct)41,382Post-transaction value (direct ownership)~$9.5 millionTransaction value based on SEC Form 4 weighted average purchase price ($227.06); post-transaction value based on June 1, 2026 market close ($227.06).Key questionsWhat was the structure and rationale behind this transaction?The sale was executed as an immediate disposition of 5,000 shares acquired through the exercise of stock options, reflecting a liquidity event tied to the vesting and exercise of long-term incentive awards rather than open-market selling of previously held equity.How does this sale compare to Reardon's historical trading activity?Since May of last year, Reardon made seven option-driven sales, with the most recent trades representing a rising percentage of remaining holdings as option capacity diminishes; the current 10.78% of direct shares sold is the highest single-transaction ratio in the recent period.What is the ongoing ownership and liquidity capacity following this transaction?Post-transaction, Reardon directly holds 41,382 shares of Common Stock (no indirect holdings), and retains 39,444 employee stock options (direct), providing continued access to potential equity sales as additional options vest and are exercised.How does the transaction align with prevailing market conditions?Ligand having delivered a 123.61% one-year total return as of the transaction date, suggesting that the liquidity event capitalized on a period of strong share price appreciation.Company overviewMetricValueRevenue (TTM)$274.48 millionNet income (TTM)$153.56 million1-year price change123.6%* 1-year price change calculated as of June 5, 2026.Company snapshotKey products include Kyprolis, Evomela, Veklury, Teriparatide, Vaxneuvance, Pneumosil, Rylaze, Nexterone, Zulresso, Noxafil-IV, Duavee, and a portfolio of specialty pharmaceuticals and vaccines.The company partners with pharmaceutical companies through license programs and sells Captisol materials.Primary customers are pharmaceutical companies and biotechnology firms.Ligand is a biotechnology company specializing in technology platforms and royalty-driven partnerships with pharmaceutical manufacturers. With a lean workforce and a diverse portfolio of commercialized and developmental-stage assets, the company leverages its expertise to enable drug discovery and development across multiple therapeutic areas.Terms and Privacy PolicyPrivacy & Cookie SettingsMore Info